We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Drugs Trigger Compulsive Gambling

By Biotechdaily staff writers
Posted on 02 Aug 2005
Drugs called dopamine agonists that are used to treat patients with Parkinson's disease have been found to be associated with habitual, compulsive gambling and large losses of money by people who previously never or only occasionally gambled.

Doctors at the Mayo Clinic (Rochester, MN, USA) learned about the gambling of 11 patients during routine clinic visits. More...
Four of the patients had never gambled before starting dopamine agonist treatment. "Most of the time, the patient came in for a routine exam and would sheepishly admit ‘I've been gambling too much,' or family members would mention that a loved one had been gambling excessively, that this behavior was totally out of character for them, and that gambling was causing problems in their lives,” said Dr. M. Leann Dodd, a Mayo Clinic psychiatrist. Losses of up to $200,000 were reported.

Researchers assessed the relationship of the gambling behavior to the patients' medications and found that all were taking dopamine agonist medications at levels appropriate for Parkinson's treatments. Eight of the patients were also taking the drug carbidopa/levodopa. The researchers located case reports in medical literature associating Parkinson's disease treatment with pathologic gambling, and compared their patients' experiences with those reported in the literature. This revealed that some patients stopped gambling when the use of a dopamine agonist was discontinued.

In seven patients, pathologic gambling developed within one to three months of reaching the maintenance dose or with dose escalation of dopamine agonist treatment. None of the patients reported compulsive gambling while treated with carbidopa/levodopa alone. The other four patients reported compulsive gambling 12-30 months after starting dopamine agonist therapy. Excessive gambling abated in all four within months of discontinuing dopamine agonist treatment. Six of the patients developed additional behavioral issues that subsided when they quit the dopamine agonist medication, including compulsive eating with weight gain, increased alcohol consumption, and hypersexuality.

The dopamine agonist drugs associated with pathologic gambling appear to be those that specifically target the D3 dopamine receptors, according to Dr. Dodd. These receptors are located in the limbic system of the brain, which controls the emotions, affect, and one's internal "reward system.” When this area of the brain is overstimulated, it can lead to more impulsive behaviors and produce a feeling of pleasure from even a previously undesirable activity, such as compulsive gambling or alcohol consumption.

The Mayo Clinic researchers explain that because pathologic gambling is so infrequently associated with dopamine agonist treatment, this potential side effect would not be a reason to stop prescribing it. Instead, doctors should urge patients to be very candid about gambling or other problems that may arise after starting medication. These findings appeared in the July 2005 issue of Archives of Neurology.



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LIAISON Murex Anti-HDV Immunoassay is the first fully automated FDA-authorized immunoassay for HDV detection in the U.S. (Photo courtesy of Diasorin)

Fully Automated Immunoassay Test Detects HDV Co‑Infection and Super-Infection

Hepatitis delta, also known as hepatitis D, is caused by the hepatitis delta virus (HDV). It is a viral liver infection that can result in one of the most severe forms of viral hepatitis.... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Industry experts gather at WHX Labs Dubai to discuss how leadership must adapt as AI and automation transform the laboratory (Photo courtesy of Shutterstock)

WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories

WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.